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to protect the liver from injury
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Overconsumption of fructose and other sugars has been linked to
nonalcoholic fatty liver disease (NAFLD); however, the sugar-associated
effects that lead to disease are poorly defined. In this issue of the JCI, Zhang
and colleagues show that the carbohydrate response element–binding
protein (ChREBP) coordinates an adaptive response to a high-fructose diet in
mice and that loss of this transcription factor leads to hepatic inflammation
and early signs of fibrosis. Intriguingly, ChREBP-dependent effects were due
to an exaggerated activation of the proapoptotic arms of the endoplasmic
reticulum stress response that is probably secondary to inappropriate
derepression of cholesterol biosynthesis. These findings suggest that a
previously unknown link exists between ChREBP and the regulation of
cholesterol synthesis that affects liver injury.

Hepatic steatosis

Nonalcoholic fatty liver disease (NAFLD)
is the ectopic accumulation of lipid in the
liver parenchyma in the absence of alcohol
overconsumption. Only recently defined
as a distinct clinical entity, NAFLD has
become the most common liver disease in
many parts of the world (1, 2). Though the
accumulation of intrahepatic triglycerides
by itself may be relatively benign, hepatic steatosis can progress to nonalcoholic
steatohepatitis (NASH), which is characterized by marked inflammation, hepatocyte death, and replacement with collagen
matrix (fibrosis). Moreover, NAFLD and
NASH are also associated with an increased
risk of developing cirrhosis and hepatocellular carcinoma (3). Although NAFLD and
NASH have become exceedingly common,
there are currently no FDA-approved therapies for this spectrum of diseases, and, thus,
treatments for NAFLD and NASH represent a significant unmet medical need.
Mouse models of NAFLD have been
developed to study this disorder in genetically tractable organisms. In general, mice
fed a fatty acid–enriched diet develop

hepatic steatosis without coincident fibrosis
or other signs of NASH (4). Diets enriched
with fructose also produce intrahepatic lipid accumulation in rodents (5), and some
epidemiologic studies support the notion
that overconsumption of sugar-sweetened
beverages containing high-fructose corn
syrup can be connected to the development
of NAFLD in humans as well (6). In mouse
models, supplementation of high-fat or fructose diets with 1% to 2% cholesterol produces liver injury reminiscent of human NASH
(7), but the relevance of such high levels of
cholesterol in the diet can be questioned.
In order for fructose and other sugars
supplemented in the diet to contribute to
complex lipids deposited in the liver, they
must first be converted to fatty acids via
de novo lipogenesis (DNL) (Figure 1). The
carbon contained in fructose must be converted to acetyl-CoA and then citrate in
the mitochondrion before entering into
the process of DNL in the cytosol. This
complex process is mediated by a number of metabolic enzymes and regulated
at both the transcriptional and posttranslational levels. Transcriptionally, the
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genes encoding these myriad enzymes
are regulated by the basic helix-loop-helix
transcription factors sterol response element–binding protein 1 (SREBP1c) and
carbohydrate response element–binding
protein (ChREBP), which are activated by
insulin (8) and intermediates of carbohydrate metabolism (9), respectively.
Originally described as a glucose-
responsive transcription factor, ChREBP
has also been shown to be highly responsive
to fructose in recent studies conducted in
both rodents and humans (10). Indeed, in
response to fructose feeding or an acute
bolus of fructose, a ChREBP-dependent
expression of the program of genes encoding various lipogenic enzymes is induced
in the liver (11, 12). Many of the genes in
this pathway, including fatty acid synthase
(Fasn), sterol-CoA desaturase (Scd1), and
acetyl CoA carboxylase 1 (Acc1) (13), are
not induced in response to fructose in mice
lacking ChREBP. Moreover, knockdown
or knockout of Chrebp prevents the development of hepatic steatosis in models of
fructose administration and in genetic
models of obesity-related NAFLD (11, 12).
However, there are also data suggesting
that the induction of this gene program may
play a protective role in liver, as mice lacking ChREBP fail to thrive or even die when
placed on extremely high-carbohydrate
diets (13). Other studies have suggested
that ChREBP-mediated induction of the
hepatokine FGF21 in response to fructose
(10) communicates with the CNS to reduce
fructose consumption (14, 15). Moreover, it
has been suggested that while activation of
ChREBP promotes fat storage, it also mitigates the development of insulin resistance
that is associated with NAFLD (16). Indeed,
many obese human subjects remain metabolically healthy, and it has been suggested
that the capacity for lipogenesis may actually be increased in these obese, metabolically normal subjects compared with metabolically unhealthy individuals (17). The
contribution of ChREBP to this phenomenon, especially in liver, remains unclear.
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Figure 1. ChREBP senses fructose to coordinate
a protective response in the liver. (A) Zhang et
al. show that fructose-mediated activation of
ChREBP in a normal liver results in increased
DNL and promotes the degradation of SREBP2.
This response is hepatoprotective, ultimately
leading to an increase in hepatic triglyceride but
no change in cholesterol levels. (B) On the other
hand, mice lacking ChREBP do not accumulate
excess triglycerides in their liver when fed a
high-fructose diet. Because fatty acids and cholesterol share a common precursor, acetyl-CoA,
carbon in fructose may flux toward cholesterol
synthesis. Moreover, SREBP2 is activated in
ChREBP-deficient hepatocytes to yield elevated
hepatic cholesterol levels that predispose to
maladaptive ER stress signaling, apoptosis, and
hepatic injury.

ChREBP and the response to
a high-fructose diet

In this issue, Zhang and colleagues
(18) have demonstrated that mice fed a
high-fructose diet exhibit selective induction of ChREBP, but not SREBP1c, in the
liver. Moreover, as previously described,
mice lacking ChREBP were protected
from high-fructose diet–induced increases
in FASN, SCD1, and ACC1 expression in
the liver and the development of hepatic steatosis, suggesting that SREBP1c
is not sufficient to mediate the adverse
effects associated with a high-fructose
diet. Despite being protected from liver
triglyceride accumulation in response to
fructose feeding, Chrebp–/– mice had unexpected increases in liver injury and hepatocyte apoptosis. ChREBP-deficient mice
showed signs of early stages of fibrosis and
NASH in response to fructose, while WT
mice did not.
Apoptosis and inflammation are key
features of progressive NASH and are both
linked to the endoplasmic reticulum (ER)
stress response (19). Under conditions of
severe distress, ER stress signaling activates the apoptotic signaling cascade (20).
However, other components of this coordinated response actually represent adaptive
responses to alleviate ER stress and are
prosurvival. Zhang and colleagues found
that a high-fructose diet failed to induce
the adaptive arms of the ER stress response
but heightened activation of the proapoptotic signaling mediators of the ER stress
pathway in Chrebp–/– mice. Notably, expression of GRP78 was reduced in fructose-fed
Chrebp–/– mice compared with expression
2534

in WT mice fed the same diet. GRP78 is
a chaperone protein that helps attenuate ER stress (21) and has not previously
been linked to ChREBP signaling. On the
other hand, Chrebp–/– mice had increased
activation of the protein kinase R–like
endoplasmic reticulum kinase/activating
transcription factor 4/C-EBP homology
protein (PERK/ATF4/CHOP) pathway
and induction of CHOP-mediated apoptosis on a high-fructose diet. Liver injury in
fructose-fed Chrebp–/– mice could be counteracted by adenovirus-mediated overexpression of GRP78, knockdown of CHOP,
or administration of a chemical chaperone
to attenuate ER stress. Together, these
findings suggest that ChREBP is a fructose-
responsive transcription factor that also
fine-tunes the ER stress response and may
promote activation of the adaptive arms in
response to high-fructose concentrations,
which can be a noxious stimulus.
Many lipid species are elevated in the
livers of patients with NAFLD and have
been implicated in the progression to
NASH. Comparisons of plasma and hepatic lipid levels have revealed an increase in
triglycerides, diglycerides, ceramides, other complex lipids, free fatty acids, and cholesterol in patients with NASH compared
with those without NASH (22). Admittedly, many of these lipids have been linked
to metabolic abnormalities and NAFLD-
associated liver injury; therefore, a case
can be made or argued for many of these
lipids as mediators of disease. Nonetheless,
studies conducted in animal models and
human studies have correlated high intrahepatic free cholesterol levels with hepat-
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ic inflammation, development of fibrosis,
and NASH (19, 23), and the addition of high
levels of cholesterol to diets fed to rodents
is particularly associated with the development of hepatic fibrosis (7). Unexpectedly,
Zhang et al. also determined that, while
hepatic triglyceride content was reduced
in Chrebp–/– mice in response to high-fructose feeding, hepatic cholesterol content
was markedly increased, coincident with
increased cholesterol biosynthesis. In
the livers of WT mice fed a high-fructose
diet, the expression of enzymes involved
in cholesterol biosynthesis was actually decreased compared with expression
in those fed a control diet. In contrast,
Chrebp–/– mice failed to suppress hepatic
cholesterol biosynthesis in response to a
high-fructose diet; however, restoration
of ChREBP expression in the livers of
Chrebp–/– mice suppressed the induction
of many genes involved in cholesterol biosynthesis and reduced free cholesterol levels. In addition, suppression of cholesterol
synthesis with atorvastatin attenuated liver injury in Chrebp–/– mice. Thus, ChREBP
may protect against fructose-induced liver
injury, in part, by repressing cholesterol
biosynthesis and cholesterol accumulation. By using a model system without
high amounts of added dietary cholesterol,
Zhang and colleagues provide strong new
evidence that cholesterol aggregation in
the liver is a trigger for liver injury and progression to NASH.
Zhang and colleagues also demonstrated that ChREBP directly interacts with
SREBP2, which is the major transcriptional regulator of genes involved in hepatic
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cholesterol biosynthesis, uptake, secretion, and transport. Their data suggest that
ChREBP directly interacts with SREBP2
and that this interaction may promote the
ubiquitination and subsequent degradation of SREBP2. This work, while quite
preliminary and requiring repetition and
validation without overexpression, suggests the existence of a new mechanism for
regulating SREBP2 activity. The teleological or physiological reasons why this carbohydrate-responsive transcription factor
would negatively regulate SREBP2 at this
level remain unclear, but could represent
a new mechanism of nutrient crosstalk. As
both cholesterol and fatty acid synthesis
require a common precursor (acetyl-CoA),
it is possible that in the absence of ChREBP,
some of the carbon that would have fluxed
into the synthesis of new fatty acids is
instead directed to flux toward cholesterol
synthesis (Figure 1). This possibility will
also need to be explored in future studies.

Concluding remarks

Taken with previous work, this study
by Zhang et al. suggests that ChREBP
plays an important protective role in the
response to fructose overload. Many
mechanistic questions remain unanswered in this initial report. For example,
does ChREBP enhance SREBP2 ubiquitination by tethering a ubiquitin ligase to
SREBP2 or by some other mechanism?
Can ChREBP also regulate ubiquitination
of other proteins that regulate fat metabolism, including SREBP1c, or is this effect
specific to SREBP2? It also remains to be
determined whether genetic variations in
ChREBP may influence the response to
fructose in humans or provide a potential
mechanism to explain why some individuals are more likely to progress from
steatosis to NASH when consuming diets
rich in fructose. Identification of such a
nutrient-gene interaction could provide

important insight into an individual’s predisposition to develop NAFLD/NASH in a
given dietary context and allow for individualized nutritional guidance.
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